ReviewFrontiers in medicine2025
New insights into microRNA in dermatological diseases.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNAs as Diagnostic and Prognostic Biomarkers in Melanoma and Non-Melanoma Skin Cancers: An Updated Review.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRs) are a class of non-coding RNA molecules that regulate gene expression post-transcriptionally. MiRs, as translational repression and/or degradation of target messenger RNAs, are critical regulators of various physiological processes, including cell proliferation, differentiation, death, and immune responses. Currently, miRs are being investigated as potential biomarkers and therapeutic targets for a range of diseases. In recent years, miRs have been reported to be implicated in several pathophysiological processes of dermatological diseases including psoriasis, skin wound, diabetic skin wound, burn, systemic sclerosis, skin tumors (melanoma, squamous cell carcinoma and basal cell carcinoma), recessive dystrophic epidermolysis bullosa, and systemic lupus erythematosus. Mechanistically, the regulation of oxidative stress, inflammation, apoptosis, and angiogenesis may account for the distinct roles of miRs in the skin. A deeper understanding of different miRs and their related regulatory targets is essential for elucidating the pathophysiology of numerous skin diseases. This review briefly summarizes roles and potential applications of miRs within the skin. The combination of miRs with novel materials or compounds may offer innovative approaches for the treatment of skin diseases. However, further research is necessary to facilitate the translation into clinical applications for dermatological diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.